SUCCESSFUL USE OF ETANERCEPT IN A PATIENT WITH POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS WITH AN OVERVIEW OF THE PREDICTORS OF A GOOD RESPONSE TO ONGOING THERAPY
https://doi.org/10.15690/vsp.v16i4.1779
Abstract
The article presents a case of polyarticular juvenile idiopathic arthritis resistant to methotrexate therapy and nonsteroidal antiinflammatory drugs. The child was prescribed a tumor necrosis factor inhibitor etanercept at a dose of 0.4 mg/kg body weight2 times/week. The treatment with etanercept induced remission of the disease, ensured the function restoration in the joints. The predictors of a good response to etanercept were the younger age, the short course of the disease, the use of a small number of immunosuppressants before prescription of etanercept, the absence of concomitant use of glucocorticosteroids, and the absence of uveitis.
Supporting agencies: Supported by Pfizer
About the Authors
Anna V. Karaseva
National Medical Research Center of Children’s Health
Russian Federation
Russian Federation
Moscow
Ekaterina I. Alexeeva
National Medical Research Center of Children’s Health; Sechenov First Moscow State Medical University
Russian Federation
Disclosure of interest: receiving grants for researches from Pfizer, Roche, Centocor, Novartis
Russian Federation
Moscow
Disclosure of interest: receiving grants for researches from Pfizer, Roche, Centocor, Novartis
Tatyana M. Dvoryakovskaya
National Medical Research Center of Children’s Health; Sechenov First Moscow State Medical University
Russian Federation
Disclosure of interest: receiving grants for researches from Pfizer, Roche, Novartis. Anna V. Karaseva confirmed the absence of a reportable conflict of interests
Russian Federation
Disclosure of interest: receiving grants for researches from Pfizer, Roche, Novartis. Anna V. Karaseva confirmed the absence of a reportable conflict of interests
References
1. Wallace CA, Giannini EH, Huang B, et al. American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2011;63(7):929–936. doi: 10.1002/acr.20497.
2. Petty RE, Southwood TR, Baum J, et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol. 1998;25(10):1991–1994.
3. Brewer EJ Jr, Bass J, Baum J, et al. Current proposed revision of JRA Criteria. JRA Criteria Subcommittee of the Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Section of The Arthritis Foundation. Arthritis Rheum. 1977; 20(2 Suppl):195–199.
4. Woo P, Wedderburn LR. Juvenile chronic arthritis. Lancet. 1998; 351(9107):969–973. doi: 10.1016/s0140-6736(05)60640-x.
5. Quartier P, Taupin P, Bourdeaut F, et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum. 2003;48(4):1093–1101. doi: 10.1002/art.10885.
6. Ringold S, Weiss PF, Beukelman T, et al. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Rheum. 2013;65(10):2499–2512. doi: 10.1002/art.38092.
7. Kearsley-Fleet L, Davies R, Lunt M, et al. Factors associated with improvement in disease activity following initiation of etanercept in children and young people with Juvenile Idiopathic Arthritis: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study. Rheumatology (Oxford). 2016;55(5): 840–847. doi: 10.1093/rheumatology/kev434.
8. Otten MH, Prince FH, Armbrust W, et al. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis. JAMA. 2011;306(21):2340-2347. doi: 10.1001/jama.2011.1671.
9. Beukelman T, Patkar NM, Saag KG, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken). 2011;63(4):465–482. doi: 10.1002/acr.20460.
10. van Dijkhuizen EH, Wulffraat NM. Early predictors of prognosis in juvenile idiopathic arthritis: a systematic literature review. Ann Rheum Dis. 2015;74(11):1996-2005. doi: 10.1136/annrheumdis-2014-205265.
11. Федеральные клинические рекомендации по ведению пациентов с юношеским артритом. — М.: Союз педиатров России; 2017. [Federal’nye klinicheskie rekomendatsii po vedeniyu patsientov s yunosheskim artritom. Moscow: Soyuz pediatrov Rossii; 2017. (In Russ).] Доступно по: http://www.pediatr-russia.ru/sites/default/files/file/kr_yua.pdf. Ссылка активна на 18.07.2017.
12. Solari N, Palmisani E, Consolaro A, et al. Factors associated with achievement of inactive disease in children with juvenile idiopathic arthritis treated with etanercept. J Rheumatol. 2013;40(2): 192–200. doi: 10.3899/jrheum.120842.
13. Geikowski T, Becker I, Horneff G; German BIKER Registry Collaborative Study Group. Predictors of response to etanercept in polyarticular-course juvenile idiopathic arthritis. Rheumatology (Oxford). 2014;53(7):1245-1249. doi: 10.1093/rheumatology/ket490.
14. Prince FH, Twilt M, ten Cate R, et al. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann Rheum Dis. 2009;68(5):635–641. doi: 10.1136/ard.2007.087411.
15. Southwood TR, Foster HE, Davidson JE, et al. Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients. Rheumatology (Oxford). 2011;50(1):189–195. doi: 10.1093/rheumatology/keq308.
16. Papsdorf V, Horneff G. Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis. Rheumatology (Oxford). 2011;50(1):214–221. doi: 10.1093/rheumatology/keq292.
17. Alexeeva EI, Namazova-Baranova LS, Bzarova TM, et al. Predictors of the response to etanercept in patients with juvenile idiopathic arthritis without systemic manifestations within 12 months: results of an open-label, prospective study conducted at the National Scientific and Practical Center of Children’s Health, Russia. Pediatr Rheumatol Online J. 2017;15(1):51. doi: 10.1186/s12969-017-0178-9.
18. Consolaro A, Bracciolini G, Ruperto N, et al. Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: Defining criteria based on the juvenile arthritis disease activity score. Arthritis Rheum. 2012;64(7):2366-2374. doi: 10.1002/art.34373.
19. Anink J, Van Suijlekom-Smit LW, Otten MH, et al. MRP8/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis. Arthritis Res Ther. 2015;17:200. doi: 10.1186/s13075-015-0723-1.
Review
For citations:
Karaseva A.V., Alexeeva E.I., Dvoryakovskaya T.M. SUCCESSFUL USE OF ETANERCEPT IN A PATIENT WITH POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS WITH AN OVERVIEW OF THE PREDICTORS OF A GOOD RESPONSE TO ONGOING THERAPY. Current Pediatrics. 2017;16(4):321-325. (In Russ.) https://doi.org/10.15690/vsp.v16i4.1779
Views:
3893
Email this article 
